Shandong Sinobioway Biomedicine Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shandong Weiming Biomedical Co., Ltd. (hereinafter referred to as "Weiming Pharmaceutical" or "Company") is an A-share public company listed on the Shenzhen Stock Exchange controlled by Weiming Group, with securities abbreviation: Weiming Pharmaceutical and securities code: 002581. The company was renamed after a major asset restructuring on October 19, 2015, known as "Zibo Wanchang Technology Co., Ltd.". The company has subsidiaries or production bases such as Weiming Biopharmaceutical Co., Ltd. (Xiamen), Tianjin Weiming Biopharmaceutical Co., Ltd., Beijing Kexing Biological Products Co., Ltd., Shandong Weiming Tianyuan Biotechnology Co., Ltd., Beijing Weiming Xida Biotechnology Co., Ltd., and Hefei Beida Weiming Biopharmaceutical Co., Ltd. One of the three major dreams of Weiming Group is to "solve China's health problems": to establish a health product supply system by developing the biopharmaceutical industry; Establishing a health service system with Chinese characteristics through the development of modern Chinese medicine; Establish a life and health management system by implementing the GHP plan. Weiming Pharmaceutical will focus on developing three major systems: drug manufacturing, new drug research and development, and product distribution, and establish a comprehensive health product supply system. Through the implementation of the "Hundred Billion Project", the following goals will be achieved by 2030: Weiming Pharmaceutical accounts for 10% of the total sales of the Chinese pharmaceutical market, accounts for 50% of the total sales of the biopharmaceutical market, and the market value of the listed company (002581) exceeds one trillion yuan; By establishing a new drug highway, Weiming Pharmaceutical will obtain 25 new drug certificates annually; Through international corporate restructuring and mergers, Weiming Pharmaceutical has become the world's largest pharmaceutical conglomerate. |
| Headquarter | Zibo |
| Establish Date | 1/18/2000 |
| Listed Code | 002581.SZ |
| Listed Date | 5/20/2011 |
| Chairman | Yue Jialin. |
| CEO | Yue Jialin. |
| Website | www.sinobiowaymed.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
